Abstract
This issue is dedicated to Prof Hamao Umezawa in appreciation of his great contributions to pioneering research on antibiotics targeting oncogenes.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Umezawa, H., Takeuchi, T., Nitta, K., Yamamoto, T. & Yamaoka, S. Sarkomycin, an anti-tumor substance produced by Streptomyces. J. Antibiot. (Tokyo) 6, 101 (1953).
Ômura, S. et al. Herbimycin, a new antibiotic produced by a strain of Streptomyces. J. Antibiot. (Tokyo) 32, 255–261 (1979).
Bishop, J. M. Cellular oncogenes and retroviruses. Annu. Rev. Biochem. 52, 301–354 (1983).
Purchio, A. F., Erikson, E., Brugge, J. S. & Erikson, R. L. Identification of a polypeptide encoded by the avian sarcoma virus src gene. Proc. Natl Acad. Sci. USA 75, 1567–1571 (1978).
Uehara, Y., Hori, M., Takeuchi, T. & Umezawa, H. Screening of agents which convert transformed morphology of Rous sarcoma virus-infected rat kidney cells to 'normal morphology: identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J. Cancer Res. (Gann) 76, 672–675 (1985).
Uehara, Y., Hori, M., Takeuchi, T. & Umezawa, H. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol. 6, 2198–2206 (1986).
Honma, Y., Okabe-Kado, J., Hozumi, M., Uehara, Y. & Mizuno, S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 1989 49, 331–334 (1989).
Okabe, M. et al. In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk. Res. 18, 867–873 (1994).
Whitesell, L. et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl Acad. Sci. USA 91, 8324–8328 (1994).
Collett, M. S., Purchio, A. F. & Erikson, R. L. Avian sarcoma virus-transforming protein, pp60src shows protein kinase activity specific for tyrosine. Nature 285, 167–169 (1980).
Ushiro, H. & Cohen, S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 255, 8363–8365 (1980).
Pike, L. et al. Characterization of platelet-derived growth factor-stimulated phosphorylation in cell membrane. J. Biol. Chem. 258, 9383–9390 (1983).
Heldin, C.-H., Ek, B. & Rönnstrand, L. Characterization of the receptor for platelet-derived growth factor on human fibroblast. J. Biol. Chem. 258, 10054–10061 (1983).
Umezawa, H. et al. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J. Antibiot. (Tokyo) 39, 170–173 (1986).
Imoto, M. et al. Kinetic studies of tyrosine kinase inhibition by erbstatin. J. Antibiot. (Tokyo) 40, 1471–1473 (1987).
Imoto, M. et al. Antitumor activity of erbstatin, a tyrosine protein kinase inhibitor. Jpn J. Cancer Res. 78, 329–332 (1987).
Isshiki, K. et al. Effective synthesis of erbstatin and its analogs. J. Antibiot. (Tokyo) 40, 1207–1208 (1987).
Isshiki, K. et al. Inhibition of tyrosine protein kinase by synthetic erbstatin analogs. J. Antibiot. (Tokyo) 40, 1209–1210 (1987).
Yaish, P. et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933–935 (1988).
Onoda, T. et al. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J. Nat. Prod. 52, 1252–1257 (1989).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no conflict of interest.
Rights and permissions
About this article
Cite this article
Imoto, M. Professor Hamao Umezawa opened up a new road for the development of molecularly targeted therapeutic drugs for cancers. J Antibiot 71, 37–38 (2018). https://doi.org/10.1038/ja.2017.139
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/ja.2017.139
